T1D Stem Cell Trial Back On; Fifth Grade Obesity; Islet Autoantibodies Predictive
(MedPage Today) -- After being hit with a clinical hold, Vertex Pharmaceuticals announced it's been given the FDA green-light to push forward on its phase I/II trial for the investigative type 1 diabetes stem cell treatment VX-880.
According to...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Diabetes | Diabetes Type 1 | Eating Disorders & Weight Management | Endocrinology | Obesity | Stem Cell Therapy | Stem Cells